500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age18+
SponsorNational Taiwan University Hospital

About this trial

This is a study to compare the treatment effect of different doses of ceftriaxone for gonorrhea.

Eligibility criteria

Qualifiers

18 years or older man, and

having oropharyngeal, anorectal or urogenital N. gonorrhoeae infection confirmed by culture or a positive NAAT

Disqualifiers

Suspicion of a complicated N. gonorrhoeae infection. Complicated N. gonorrhoeae infection is defined as the presence of epididymitis, arthritis, bacteremia, conjunctivitis, or disseminated gonococcal infection.

Use of systemic cephalosporins, doxycycline, or azithromycin at the screening visit or within 30 days prior to the enrollment visit is prohibited. Participants who require immediate antibiotic treatment at the screening visit, based on clinician judgment or shared decision-making with the participant, without awaiting PCR or culture confirmation, will be excluded from the study. Use of doxycycline for post-exposure prophylaxis (Doxy-PEP) is permitted.

A NAAT test positive for C. trachomatis or M. genitalium at the screening visit.

A history of allergy or intolerance to ceftriaxone, penicillins, or lidocaine, in alignment with the contraindications listed in the Sintrix (ceftriaxone) injection package insert. Allergy or intolerance is defined as the occurrence of adverse symptoms following antibiotic administration, including but not limited to skin rash, pruritus, dyspnea, angioedema, anaphylaxis, dizziness, nausea, vomiting, headache, or diarrhea. Laboratory abnormalities include cytopenias, eosinophilia, and elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or creatinine. Penicillins include natural penicillins (e.g., penicillin G), aminopenicillins (e.g., amoxicillin, ampicillin), penicillinase-resistant penicillins (e.g., oxacillin, dicloxacillin), extended-spectrum penicillins (e.g., piperacillin), and other agents classified within the penicillin class.

Trial design

Treatments tested in this trial

  • ceftriaxone 500-mg
  • ceftriaxone 1000-mg

Treatment groups

400 Participants
are divided into 2 treatment groups

Sponsors and collaborators

National Taiwan University Hospital

Lead sponsor

National Taiwan University Hospital Hsin-Chu Branch

Collaborator

Far Eastern Memorial Hospital

Collaborator

National Taiwan University Hospital, Yun-Lin Branch

Collaborator